Famotidine

In view of the clinical status of high incidence of peptic ulcer, H2 receptor antagonists have long been one of the core options for acid suppression therapy, and famotidine is an upgraded variety of this class of drugs with stronger acid suppression effect and lower adverse reactions. It competitively blocks H2 receptors in gastric parietal cells, and significantly inhibits basal gastric acid secretion and gastric acid secretion stimulated by food, histamine and other factors. Its acid suppression intensity is more than 20 times that of cimetidine, and it has no obvious anti-androgen effect. Clinically, it can be used for the treatment of gastric and duodenal ulcers, reflux esophagitis, and Zollinger-Ellison syndrome, and can also be used for the prevention of upper gastrointestinal bleeding under stress conditions. The applicable population covers adult and pediatric patients with peptic ulcer.

The global market size of famotidine API is stable at around USD 120 million. In recent years, affected by the rising prevalence of digestive system diseases and the expansion of over-the-counter drug use scenarios, the compound annual growth rate has remained at 3.8%. China is the core supplier of famotidine API in the world, with a production capacity accounting for more than 75% of the global total. The top 3 enterprises together account for more than 60% of the domestic market share. With the implementation of the centralized procurement policy, the requirements for API quality standards continue to improve, and the market share of suppliers with strong compliance and excellent impurity control capabilities shows a trend of concentration.

CATO can provide a full set of impurity reference standards for famotidine API. All products meet the access requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, with sufficient spot inventory. It can quickly respond to the full-process needs of API manufacturers in impurity research, quality control and compliance declaration, and help customers shorten the R&D cycle and reduce quality risks.